Mitochondrial Dysfunction and Insulin Resistance: The Contribution of Dioxin-Like Substances by Lee, Hong Kyu
D I A B E T E S  &  M E T A B O L I S M   J O U R N A L
This is an Open Access article distributed under the terms of the Creative Commons At-
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Copyright © 2011 Korean Diabetes Association  http://e-dmj.org
Diabetes Metab J 2011;35:207-215
Mitochondrial Dysfunction and Insulin Resistance: 
The Contribution of Dioxin-Like Substances
Hong Kyu Lee
Department of Internal Medicine, Eulji University School of Medicine, Seoul, Korea
Persistent organic pollutants (POPs) are known to cause mitochondrial dysfunction and this in turn is linked to insulin resistance, 
a key biochemical abnormality underlying the metabolic syndrome. To establish the cause and effect relationship between expo-
sure to POPs and the development of the metabolic syndrome, Koch’s postulates were considered. Problems arising from this ap-
proach were discussed and possible solutions were suggested. In particular, the difficulty of establishing a cause and effect rela-
tionship due to the vagueness of the metabolic syndrome as a disease entity was discussed. Recently a bioassay, aryl-hydrocarbon 
receptor (AhR) trans-activation activity using a cell line expressing AhR-luciferase, showed that its activity is linearly related with 
the parameters of the metabolic syndrome in a population. This finding suggests the possible role of bioassays in the analysis of 
multiple pollutants of similar kinds in the pathogenesis of several closely related diseases, such as type 2 diabetes and the meta-
bolic syndrome. Understanding the effects of POPs on mitochondrial function will be very useful in understanding the integra-
tion of various factors involved in this process, such as genes, fetal malnutrition and environmental toxins and their protectors, 
as mitochondria act as a unit according to the metabolic scaling law. 
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The Sulwon Award for Scientific Achievement is the Korean 
Diabetes Association's highest scientific award and honors an 
individual who has excellently contributed to the progress in 
the field of diabetes and metabolism. Sulwon award is named 
after an emeritus professor Eung Jin Kim, who founded Kore-
an Diabetes Association. 
  Prof. Hong Kyu Lee received the second Sulwon Award at 
36th AuCongress of Korean Diabetes Association, October 16-
17, 2010 at Busan, Korea.
INTRODUCTION TO INSULIN RESISTANCE 
AND THE MITOCHONDRIA-BASED MODEL 
OF METABOLIC SYNDROME
Insulin resistance is a common biochemical abnormality pre-
ceding type 2 diabetes and other associated diseases. In 1988, 
G. Reaven proposed that this state should be studied as a dis-
ease and named it syndrome X, or unknown syndrome. Epi-
demiologic studies revealed the risk factors of this disease and 
ultimately the cause(s). The World Health Organization (WHO) 
gave a new name to this disease, metabolic syndrome, and es-
tablished its diagnostic criteria in 1998. The metabolic syn-
drome is defined as the presence of at least 3 of the following 
symptoms or phenotypes in an individual; abdominal obesity 
(measured by waist circumference), high serum triglyceride 
level, low serum high density lipoprotein (HDL) level, hyper-
glycemia, and high blood pressure. 
  In 1998, my colleagues and I found that blood mitochon-
drial DNA (mtDNA) density in peripheral blood cells was low-
er in those subjects who would go on to develop diabetes in 2 
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years, in comparison to those who would not. Furthermore, 
people with lower blood mtDNA density had high blood pres-
sure, high serum triglyceride levels and a high waist circum-
ference ratio. These findings suggest that a decrease in mtDNA 
density in blood cells is causally related to the metabolic syn-
drome. In the following years, we accumulated evidence sug-
gesting that mitochondrial dysfunction might be the central 
abnormality causing insulin resistance, and it might also be 
responsible for the insulin secretion defect found with type 2 
diabetes. We presented evidence in support of this hypothesis 
and this evidence underwent several reviews [1,2]. 
  In this lecture, I will argue again that the metabolic syndrome 
is a state of mitochondrial dysfunction, which is, in turn, iden-
tical to the state of insulin resistance. In this interpretation, 
cause(s) of type 2 diabetes are identical to cause(s) of the met-
abolic syndrome, and type 2 diabetes is later stage of this altered 
body state. The insulin secretion defect in type 2 diabetes might 
arise from the insulin resistance state per se, as it is a state of 
mitochondrial dysfunction and good mitochondrial function 
is needed for good insulin secretion. This view of the metabol-
ic syndrome is thus narrower than the generally held view, 
which includes full-blown type 2 diabetes and atherosclerosis 
within the metabolic syndrome (Fig. 1). 
MITOCHONDRIA-BASED MODEL OF THE 
METABOLIC SYNDROME: A SPECIAL CASE 
OF METABOLIC SCALING
Another important aspect of the mitochondria-based model is 
that it is a special case of the scaling law. We know that many 
body parameters correlate with body size; the bigger the body 
size, the larger the metabolism rate becomes. It is well known 
that the metabolic rate of mammals increases when body mass 
increases. There is a linear relationship between metabolic rate 
(Y), and body mass (M) characterized by the equation, Y= 
Y0×M(body mass)
3/4. 
  This law tells us that the larger the body size, the greater the 
decrease in the mass specific metabolic rate (Y/M). Most im-
portantly, it was found that this relationship holds down to in-
dividual cells and their mitochondria as well as mitochondrial 
electron transfer chain activities [3]. In other words, if the body 
size of a mammal increases, its unit (cell or mitochondrial) 
metabolic power decreases (Fig. 2). We found that mitochon-
drial DNA copy numbers are decreased in the metabolic syn-
drome, and this is negatively correlated with serum insulin re-
sponses in health young male medical students. From these 
results, we reasoned that the metabolic syndrome is the result 
of the metabolic scaling law in action, in that body metabo-
lism is changing in order to adapt to decreasing mitochondrial 
function. In other words, the state of insulin resistance is an 
adaptation of the body to the decrease in unit mitochondrial 
function. This reasoning is also discussed in detail in a previ-
ous paper [2]. 
  One of the key principles of this process is the adaptation of 
enzymes to the body temperature of 37°C. At this temperature, 
most enzymes have the lowest Gibbs free energy. If mitochon-
drial dysfunction leads to a decrease in heat production, body 
temperature would be lower, and this has to be compensated 
for by an increase in fat mass (insulation), increased heat pro-
duction, and thus more mitochondrial mass and nutrient sup-
ply, which in turn would require higher levels of serum insu-
lin, glucose, and triglycerides.
  Metabolic scaling is the only “law” generally accepted in bi-
ology. The term “law” is not debated in this usage. Scaling is 
applicable not only to the metabolic rate but to many aspects 
of body states, such as the relationship between body size and 
brain mass, aorta circumference, blood volume and almost every 
Fig. 1.  Pathogenesis of the metabolic syndrome as a special 
state of mitochondrial dysfunction. Various phenotypes, such 
as insulin deficiency and insulin resistance are pathophysio-
logically defined states, while type 2 diabetes, hypertension 
and obesity are well-defined specific disease states. Coronary 
heart disease and cancer might be considered either specific 
diseases or complications (or more appropriately, later stages) 
of preceding disease states. In this model, diabetes and CADs 
are not results of obesity, but its later stage phenotypes. CVD, 
cardiovascular disease; NMD, neuromuscular disease; 
NAFLD, nonalcoholic fatty liver disease.
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aspect of body metabolism. This phenomenon is also known 
as “allometry”; where the size of every part of body is quantita-
tively related to the whole (mass). It is not surprising that bone 
mass and bone strength should increase along with the body 
size of an animal; lung volume should increase with increasing 
metabolic demand, kidney size also increases in order to deal 
with the increasing metabolic waste of an increasing body 
mass and blood volume. This concept is illustrated in Fig. 3.
  This kind of relationship predicts that if body mass increas-
es (obesity), the circulatory system will enlarge in adaptation. 
However, there will be limit to this adaptation, in particular 
when unit cell (or mitochondrial function) is decreased, as in 
the insulin resistance state, a mismatch will develop. If heart 
metabolism (i.e., cardiac output) did not increase in order to 
adapt to increasing demand from the whole body, the result 
would be heart failure. If the coronary artery does not need to 
supply as much blood to the heart due to a decrease in energy 
demand, the coronary artery should decrease in size. I suspect 
that this may be a reason why coronary heart disease develops 
in type 2 diabetes.
  These novel explanations might be unfamiliar to most clini-
cians, as they are biophysical and based mostly on bioenerget-
ics. While many aspects of this theory need experimental sup-
port, I believe that a mitochondria-based model fits well with 
reality.
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Fig. 2.  Metabolic scaling relation between body size and metabolic rate. Panel (A) shows metabolic rate increases (watt) with in-
creasing body mass (kg) across animal species, from mitochondrion to elephant. In Panel (B), the logarithm of the mass-specific 
metabolic rate, W/g, versus the body mass, M (g), for mammals is plotted in a logarithmic scale. The mass-specific metabolic rate 
declines as body mass increases. Panel (C) shows the relationship between changes in 24-hour energy expenditure (Δ 24-EE) and 
Δ weight after adjustment of 24-EE for fat-free mass (FFM), fat mass (FM), waist to thigh ratio (WTR), and age. Weight change 
is accompanied by a change in energy expenditure in Pima Indians. A long-term adaptation process normalizes the relationship 
between body mass and metabolic rate, suggesting that an adaptive process is operating (Panel D). Arrows 1A and 2A depicts 
metabolic adaptation, which leads to a quick decrease in the metabolic drive and a small weight change. Arrows 1B and 2B de-
pict poor metabolic adaptation, which leads to a sustained metabolic drive and a larger weight change.
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CAUSES OF TYPE 2 DIABETES
There are many “causes” in medicine; in fact “causes” are di-
verse in different disease states, and diseases are themselves 
diverse and variously defined. These features are illustrated in 
Fig. 1. Diabetologists may regard coronary heart disease as a 
complication of type 2 diabetes, while cardiologists might 
consider diabetes to be a cause of coronary heart disease. This 
difference arises because specialists treat a limited group of 
people with specific diseases, such as patients with type 2 dia-
betes or coronary heart disease. They examine why their pa-
tients get those illnesses (causes) and what might happen to 
them as a result (complications).
  Causes are divided into genetic and environmental causes, 
which can in turn be divided again into their individual com-
ponents. Medicine adopts the division of “causes” when there 
are different treatments or prevention methods available for 
these different causes. For example, diabetes is caused by insu-
lin deficiency and it is treated with an insulin supply. If you 
were to ask whether we could restore insulin deficiency, the 
answer is no. If you were to further ask why we could not do 
this, there would be another answer(s); such as ageing, etc. In 
fact, we do not know.
  We are, however, fairly certain of all of these chains of events 
from the genetic make-up (factors) and epigenetic changes 
which occur during development, particularly during the fetal 
stage, such as malnutrition and environmental factors. In the 
mitochondria-based model, there are 3 basic causes; genes and 
developmental and environmental toxins (and protectors). I 
will explain why the continuous accumulation of environmen-
tal toxins or so called persistent organic pollutants (POPs) in 
our body might be one of the most important factors.
Genetic causes of type 2 diabetes; contribution of the 
mitochondrial genome
Humans and other animals have two genetic systems; a nucle-
ar genome and a mitochondrial genome. The contribution of 
nuclear genes to type 2 diabetes is well known and will not be 
discussed here. However, mtDNA, the second genome, needs 
attention. It is now well established that certain mtDNA poly-
morphism and haplotypes are either susceptible (16189 T>C, 
haplotype B and F) or resistant (haplotype N9a) to type 2 dia-
betes among Asians [5,6]. Readers are reminded that these 
findings were not confirmed in Europe and most European 
geneticists do not consider mtDNA in their study of type 2 di-
abetes, although a recent study in Italy showed that the 16189 
T>C variant is associated with the metabolic syndrome [7].
  These facts describe the essential part of the mitochondria-
based model. This model suggests that an analysis of the ge-
netic effect(s) of nuclear genes(s) should consider the inde-
pendent effects of the mitochondrial genome, at least in Asia.
  I am well aware that mitochondrial dysfunction does not 
cause the metabolic syndrome in general. Children born with 
mitochondrial DNA mutations manifest various clinical syn-
dromes, such as mitochondrial encephalopathy, lactic acidosis 
and stroke-like episodes (MELAS), myoclonic epilepsy with 
ragged red fibers (MERRF), and Lebers hereditary optic neu-
ropathy (LHON). These disease states are associated with a 
low body mass, not obesity. However, a family with a special 
mtDNA mutation exhibited hypertension and hyperlipidemia, 
suggesting that the metabolic syndrome might result from a 
mtDNA abnormality [8]. 
Malnutrition during fetal and early life; thrifty phenotype 
and mitochondrial state
Exposure to malnutrition early in life predisposes an individu-
al to type 2 diabetes and several chronic diseases, including the 
metabolic syndrome. As shown in Fig. 1, if the mitochondria-
Fig. 3.  In whole-body metabolism, energy supply and energy 
demand are tightly linked, and the metabolism of its parts is 
quantitatively related (allometry) to whole-body mass. The 
larger the body, the bigger the parts, but the mass specific met-
abolic rate decreases (From Weibel ER. Nature 2002;417:131-
2, with permission from Nature Publishing Group) [4]. 
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based model is correct, fetal malnutrition would induce an al-
tered mitochondrial state. We have proved this in an animal 
experiment [9]. 
Environmental toxins; POPs 
The most important cause of type 2 diabetes and the metabolic 
syndrome is environmental. Something bad was introduced 
during industrialization and is increasing in the environment. 
We know that it is noninfectious; the usual suspects are “POPs.” 
POPs are defined as “chemical substances that persist in the 
environment, bio-accumulate through the food web, and pose 
a risk of causing adverse effects to human health and the envi-
ronment” by the Stockholm Convention. It identified 12 POPs 
initially and subsequently added 9 more. 
  Pesticides: aldrin, chlordane, DDT, dieldrin, endrin, hepta-
chlor, hexachlorobenzene, mirex, toxaphene, chlordecone, al-
pha hexachlorocyclohexane, beta hexachlorocyclohexane, lin-
dane, pentachlorobenzene 
  Industrial chemicals: hexachlorobenzene, polychlorinated 
biphenyls (PCBs), hexabromobiphenyl, hexabromodiphenyl 
ether and heptabromodiphenyl ether, pentachlorobenzene, 
perfluorooctane sulfonic acid, its salts, and perfluorooctane 
sulfonyl fluoride, tetrabromodiphenyl ether and pentabromo-
diphenyl ether 
  Their by-products: hexachlorobenzene; polychlorinated 
dibenzo-p-dioxins and polychlorinated dibenzofurans (PCDD/ 
PCDF), and PCBs, alpha hexachlorocyclohexane, beta hexa-
chlorocyclohexane and pentachlorobenzene. 
  (Source: http://chm.pops.int/Convention/tabid/54/lan-
guage/en-US/Default.aspx.) 
ESTABLISHMENT OF POPS AS A CAUSE OF 
DIABETES
Association studies 
These usual suspects were first examined by Baillie-Hamilton 
[10], in 2002 . She wondered if the industrial use of new chem-
icals after World War II might be responsible for the obesity 
epidemic, simply because their appearances coincided. They 
have been firmly indicted by a Korean epidemiologist, Lee and 
her colleagues [11,12], who confirmed the association be-
tween serum POPs levels and type 2 diabetes and the meta-
bolic syndrome.
  Using the NHANES 1999-2000 data set, she found six POPs 
(2,2,4,4,5,5-hexachlorobiphenyl [PCB153], 1,2,3,4,6,7,8-hep-
tachlorodibenzo-p-dioxin [HpCDD], 1,2,3,4,6,7,8,9-octachlo-
rodibenzo-p-dioxin [OCDD], oxychlordane, p,p-dichlorodi-
phenyltrichloroethane [DDE], and trans-nonachlor) that were 
detected in at least 80% of study subjects and body load of per-
sistent organic pollutants (sum of 6 POPs) was associated with 
the prevalence of diabetes in a strong dose-dependent manner. 
Observations showing an association between POPs and dia-
betes soon followed from Denmark (Greenland Inuit), Tai-
wan, Japan, the Slovak Republic and many other countries. 
These data appear too strong to deny a causal association. How-
ever, the mere presence of a statistical association between two 
variables, POPs and the diabetes/metabolic syndrome in our 
case, does not establish a cause and effect relationship.
  It is important to note that several prospective studies of se-
lected POPs performed in occupational or accidental high ex-
posure settings reported inconsistent results, particularly for 
2,3,7,8-TCDD. Also, the decreasing trend of organochlorine 
POPs during recent decades is inconsistent with the current 
trend towards an increased prevalence of type 2 diabetes [13]. 
Animal studies 
In order to establish the cause and effect relationship between 
POP exposure and development of the diabetes/metabolic syn-
drome, experimental studies are needed. We have paid partic-
ular attention to the herbicide atrazine and related triazine 
herbicides because they have been extensively used in the USA 
since the early 1960s, which corresponds to the beginning of 
the present obesity epidemic and they are also known to in-
hibit tissue respiration in mussels. Atrazine is routinely found 
as a contaminant in surface and ground water in the USA. It is 
known to bind irreversibly to the photosystem II complex on 
the thylakoid membranes in chloroplasts, an essential compo-
nent of photosynthesis, and we found that it inhibits the elec-
tron transport of mitochondria as well. We fed rats with atra-
zine-containing water and found that they develop insulin re-
sistance, a fatty liver and abdominal obesity [14].
  Recently, Ruzzin et al. [15] exposed Wistar rats to lipophilic 
POPs for 28 days by feeding them a high-fat diet containing 
crude fish oil obtained from farmed Atlantic salmon, which 
are contaminated with several organic pollutants. They mea-
sured body weight, whole-body insulin sensitivity, POP accu-
mulation, and the lipid and glucose homeostasis of contami-
nated-salmon-oil-fed rats and compared measurements in 
rats fed decontaminated (with activated charcoal) salmon oil. 
Rats exposed to crude, but not refined, salmon oil developed 212
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insulin resistance, abdominal obesity, and hepato-steatosis. 
They concluded that exposure to POPs commonly present in 
the food chain leads to insulin resistance and associated meta-
bolic disorders. These results are very convincing, but human 
studies are needed in order to unequivocally prove that POP 
exposure is a cause of the diabetes/metabolic syndrome. 
Nested case control study 
We cannot conduct this feeding experiment in humans. In or-
der to establish a cause and effect relationship in humans, Lee 
DH approached the Coronary Artery Risk Development in 
Young Adults (CARDIA) study group and measured POP lev-
els in their population before the development of disease phe-
notypes. She reported that serum levels of some POPs (in par-
ticular, trans-nonachlor and highly chlorinated PCBs) at CAR-
DIA year 2 were associated with the incidence of type 2 diabe-
tes over the next 18 years, especially in obese persons [13]. 
Parallel to the prediction of type 2 diabetes, many statistically 
significant associations of POPs with metabolic conditions ap-
peared at low doses, forming inverted U-shaped dose-response 
relationships. 
  Among organochlorine pesticides, the presence of p,p′-DDE 
predicted higher body mass index (BMI), triglycerides, and 
homeostasis model assessment of insulin resistance (HOMA-
IR) and lower HDL-cholesterol (HDL-C) most consistently at 
year 20 after adjusting for baseline values. The presence of 
oxychlordane, trans-nonachlor, and hexachlorobenzene also 
significantly predicted higher triglycerides. Persistent PCBs 
with ≥7 chlorides predicted higher BMI, triglycerides, and 
HOMA-IR and lower HDL-C at year 20 with similar dose-re-
sponse curves. Simultaneous exposure to various POPs in the 
general population appeared to contribute to the development 
of obesity, dyslipidemia, and insulin resistance. The authors 
concluded that POP exposure may contribute to excess adi-
posity and other features of dysmetabolism [16]. 
  Because POPs are well-known endocrine disruptors, they 
reasoned that serum POP levels showed strong associations at 
relatively low exposures, thus an inverted U-shape relation-
ship characterizes this association. Unlike the traditional para-
digm of cellular toxicity in which a linear dose-response rela-
tionship is the rule, the inverted U-shaped responses of endo-
crine disruptors have been well known among toxicologists. 
PROBLEMS IN ESTABLISHING A CAUSE AND 
EFFECT RELATIONSHIP BETWEEN POP 
EXPOSURE AND DEVELOPMENT OF THE 
METABOLIC SYNDROME
A cause and effect relationship between a microorganism and 
disease is usually established when Koch’s postulates are met; 
1) the microorganism must be found in abundance in all or-
ganisms suffering from the disease, but should not be found in 
healthy organisms; 2) The microorganism must be isolated 
from a diseased organism and grown in pure culture; 3) The 
cultured microorganism should cause disease when intro-
duced into a healthy organism; and 4) the microorganism must 
be re-isolated from the inoculated, diseased experimental host 
and identified as being identical to the original specific caus-
ative agent. The evidence provided above would be sufficient 
enough to meet Koch’s postulates. As POPs are inorganic, very 
stable and persistent, the issues of isolation for POPs and pure 
culture as required in postulates 2 and 4 are irrelevant. 
  We are dealing with a novel problem here; the suspected 
causative agents, POPs, are not a single agent, but are diverse, 
very similar to one another, interact with each other (variously 
acting as antagonist or agonist), and exhibit a “low dose effect.” 
How can we “know” if they cause a disease, when they accu-
mulate over many years and exhibit such complicated behav-
iors? There is another problem as well, because the metabolic 
syndrome is not a well-defined disease entity. Lee DH found 
that serum levels of organochlorine pesticides are more closely 
associated with type 2 diabetes, and abdominal obesity and 
high serum triglyceride levels and furans and dioxins are more 
closely associated with hypertension. Should we divide the 
metabolic syndrome into two subgroups: type 1, organochlo-
rine pesticide syndrome and type 2, furan/dioxin syndrome? 
Furthermore, there are 5 or more phenotypes characterizing 
the metabolic syndrome and only 3 of them are needed for a 
diagnosis. What would be the merit of diagnosing a disease, 
such as the metabolic syndrome, if serum POP levels (or bur-
den of body POPs) is high? We need to reduce POP levels any-
way, regardless of the subject’s phenotype. It might be worth-
while to note that the NHANES data showed that POP levels 
interact with BMI in determining type 2 diabetes. When POP 
levels were lower, diabetes prevalence was not associated with 
BMI, while obese people with high serum POP levels had an 
increase in diabetes prevalence.213
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BIOASSAY OF SERUM DIOXIN-LIKE 
ACTIVITY, A BREAKTHROUGH?
Measuring exposure to POPs in humans is particularly diffi-
cult as the current method of POP detection usually requires a 
large serum sample. There is no stored serum sample large 
enough to test this concept epidemiologically, only a few milli-
liters at best. Furthermore, measuring POPs chemically with 
the use of high resolution GC/MS, which is the gold standard, 
is very difficult, prohibitively expensive and requires a machine 
devoted to this use, facility and people. 
  We wondered if there would be an alternative method for 
measuring the body burden of POPs and found the CALUX 
assay promising. This assay has been successfully used by en-
vironmental scientists for the screening of dioxin-like substanc-
es for many years. It takes advantage of the fact that dioxin and 
dioxin-like substances act through aryl-hydrocarbon recep-
tors almost exclusively. If one were to make a cell line trans-
fected with the plasmid expressing aryl-hydrocarbon receptor 
(AhR) gene, it would respond to dioxin or dioxin-like chemi-
cal substances. If AhR is Chemical (dioxin-like substances) Ac-
tivated and Luciferase Expression (CALUX) is measured, one 
could calculate the amount of dioxin or dioxin-like substances 
in samples. 
  Recently, KimPak Y at Kyung Hee University developed a 
modified CALUX assay and tested sera of pre-diabetes or type 
2 diabetes for their AhR transactivation activity (AhRTA). To 
our surprise, the AhRT activities of sera were closely associat-
ed with the parameters of the metabolic syndrome. Results 
were consistent with the conclusion that serum dioxin-like ac-
tivity is a “cause” of insulin resistance and type 2 diabetes. In 
short, AhRT activities and parameters of the metabolic syn-
drome were linear (Submitted for publication). This linear re-
lationship is in stark contrast with the conclusion obtained 
from CARDIA cohorts, where a “low dose effect” predomi-
nates. I wonder if this study could be extended to a nested case 
control study like CARDIA.
CRITIQUES OF THE MITOCHONDRIAL 
HYPOTHESIS
Critics of the mitochondria-based model argue that excessive 
calorie intake and lack of exercise are the primary causes of 
obesity, and thus the metabolic syndrome. It is frequently ar-
gued that even though mitochondrial dysfunction is present 
in this state, it is regarded as secondary to obesity, induced by 
overfeeding or lack of exercise. Indeed, one can surely bring 
on obesity by consuming a high-fat diet. However, these cri-
tiques dismiss some important facts; 1) only certain high-fat 
diets cause obesity in susceptible animals, (this “high-fat diet” 
was found to be contaminated with POPs [unpublished obser-
vation]); 2) the propensity to return to previous body weight 
after fat removal or transplantation suggests the presence of a 
strong drive to maintain body weight; and 3) obese people do 
not eat more, once a certain increase in body weight is reached. 
I will not provide references supporting all of these facts, but I 
want to emphasize that the current gold standard of diet as-
sessment, the doubly labeled water test, which is held to pro-
vide unequivocal evidence for excessive calorie intake as a 
cause of obesity, might be based on an erroneous assumption.
  A basic assumption of the doubly labeled water (DLW) 
method to measure energy expenditure is that H of body wa-
ter only leaves the body pool in the form of water. If deuterium 
(as a measure of H) is sequestered in anything other than body 
water during a DLW study, an overestimation of water turn-
over and therefore an underestimation of CO2 production 
would result, thus indicating a high metabolic rate. Hydrogen 
is incorporated into fat, and deuterium incorporation into 
body fat has the greatest potential to be an error of the DLW 
method. This is significant and presents a potentially serious 
error in the determination of energy requirements, especially 
in those subjects with different intrinsic rates of fat synthesis. 
Haggarty et al. [17] reported de novo lipogenesis and choles-
terol synthesis over the typical duration of a DLW study (2 
weeks), as well as the likely effects of sequestration on the per-
formance of the DLW method in adult human subjects. 
  Using whole-body fatty acid synthesis, they found little evi-
dence of an error on DLW-derived CO2 production for five of 
the six subjects studied; mean -0×5%, range 0 to -1×3%. How-
ever, there was a subject whose fatty acid synthesis rate was al-
most 10 times faster than others, was hypertrigliceridemic (five 
times higher) and had a slightly higher body fat mass. They ar-
gued that the very high value for circulating triacylglycerols in 
this subject was indicative of a high rate of de novo lipid syn-
thesis and that the assumptions underlying the calculation of 
whole-body lipogenesis (assumed identical between subjects) 
may be invalid. In other words, in subjects with hypertriglyc-
eridemia, the DLW test might result in rather high estimates 
of energy expenditure. 
  In the metabolic syndrome (with hyertriglyceridemia), a 214
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DLW test would result in a high estimate of energy expendi-
ture compared with a diet intake measure (which is normal for 
the body mass). One would arrive at an erroneous conclusion 
that obese subjects under-report their dietary intake. 
SUMMARY AND CONCLUSIONS
I presented evidence that POPs might be a cause of the meta-
bolic syndrome, probably acting through AhR and a mito-
chondrial mechanism. There is a huge body of evidence sup-
porting this hypothesis. However, establishing a cause and ef-
fect relation between POP exposure and the development of 
the metabolic syndrome will be difficult, because of the diver-
sity of POPs and their bizarre low dose effect. This conundrum 
might be resolved by our finding that serum AhRT activity is 
linearly related with parameters of the metabolic syndrome in 
nested case control studies. 
  The mitochondria-based model could be considered as a 
special application of the metabolic scaling law as applied to a 
group of people with a specific disease. This model will be very 
useful in integrating various factors acting on mitochondrial 
function, such as genes, fetal malnutrition and environmental 
toxins and protectors. I believe that “genomic medicine” should 
be based on the mitochondrial genome, not only the nuclear 
genome, as our model suggests. Our model also suggests that 
if we could improve mitochondrial function, insulin resistance 
might decrease. This prediction is validated by recent studies 
with hydrogen gas, which quenches free radicals and stimu-
lates mitochondrial function [18], and by studies with bile acid 
sequestrants, which could remove POPs and improve the met-
abolic syndrome [19]. 
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